AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38172325 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote measurements via videoconferencing
Number of subjects: 33
Study 38172325 — intervention group
Group type: COMPARATOR
Intervention: In-person measurements with research staff
Number of subjects: 33
Study 38172345 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction
Number of subjects: 10
Study 38172458 — intervention group
Group type: EXPERIMENTAL
Intervention: Alveolar ridge splitting (ARS) with guided bone regeneration (GBR) using simvastatin (SMV) gel mixed bone graft and a barrier membrane with simultaneous implant placement
Number of subjects: 22
Study 38172458 — intervention group
Group type: COMPARATOR
Intervention: Guided bone regeneration (GBR) without simvastatin (SMV) gel
Number of subjects: 22
Study 38172659 — intervention group
Group type: EXPERIMENTAL
Intervention: Kiosk BP monitoring
Number of subjects: 0
Study 38172659 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-measured BP
Number of subjects: 0
Study 38172659 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-measured BP
Number of subjects: 0
Study 38172659 — intervention group
Group type: COMPARATOR
Intervention: Kiosk BP
Number of subjects: 0
Study 38172712 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy meal-replacement plan (MRP) (∼810 kcal/day) for 12 weeks
Number of subjects: 24
Study 38172712 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC), N=25 (15 males, age 48.3±6.6 years)
Number of subjects: 24
Study 38172750 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased cognition (MMSE score < 25)
Number of subjects: 119
Study 38172750 — intervention group
Group type: COMPARATOR
Intervention: Intact cognition (MMSE score ≥ 25)
Number of subjects: 119
Study 38172780 — intervention group
Group type: EXPERIMENTAL
Intervention: ABLE 2.0 intervention
Number of subjects: 78
Study 38172875 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 84
Study 38172875 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 84
Study 38172930 — intervention group
Group type: EXPERIMENTAL
Intervention: CDSS-OPTIMED intervention (software program providing weekly personalized medication recommendations)
Number of subjects: 7
Study 38172930 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 7
Study 38172949 — intervention group
Group type: EXPERIMENTAL
Intervention: CEUS-CT/MRI fusion imaging (FI)
Number of subjects: 248
Study 38172949 — intervention group
Group type: EXPERIMENTAL
Intervention: CEUS addition to US-FI
Number of subjects: 248
Study 38172949 — intervention group
Group type: EXPERIMENTAL
Intervention: CEUS-CT/MRI fusion imaging (FI) guided RFA
Number of subjects: 248
Study 38172973 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (1.5 mA for 20 min)
Number of subjects: 30
Study 38172973 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 30
Study 38172973 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 30
Study 38172996 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 μg/day B12 supplementation
Number of subjects: 68
Study 38172996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 38173006 — intervention group
Group type: EXPERIMENTAL
Intervention: AAN-equipped TIGER
Number of subjects: 16
Study 38173006 — intervention group
Group type: COMPARATOR
Intervention: Original TIGER
Number of subjects: 16
Study 38173041 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 88
Study 38173041 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient activation
Number of subjects: 88
Study 38173041 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity and non-motor symptoms interaction
Number of subjects: 88
Study 38173041 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity and motor symptoms interaction
Number of subjects: 88
Study 38173167 — intervention group
Group type: COMPARATOR
Intervention: i-CBT-only
Number of subjects: 56
Study 38173167 — intervention group
Group type: EXPERIMENTAL
Intervention: i-CBT with stepped care
Number of subjects: 56
Study 38173937 — intervention group
Group type: EXPERIMENTAL
Intervention: V-V ECMO
Number of subjects: 0
Study 38174101 — intervention group
Group type: EXPERIMENTAL
Intervention: Parkinson's disease (PD)
Number of subjects: 1648
Study 38174101 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive supranuclear palsy (PSP)
Number of subjects: 1648
Study 38174101 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1648
Study 38174147 — intervention group
Group type: EXPERIMENTAL
Intervention: LCPT (Life cycle pharma tacrolimus) orally once daily at a starting dose of 0.13 mg/kg/day based on actual body weight.
Number of subjects: 0
Study 38174154 — intervention group
Group type: EXPERIMENTAL
Intervention: Arteriogram
Number of subjects: 94
Study 38174154 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocalcemic stimulation
Number of subjects: 94
Study 38174154 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective venous sampling (SVS)
Number of subjects: 94
Study 38174564 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate antihypertensive treatment
Number of subjects: 4071
Study 38174564 — intervention group
Group type: COMPARATOR
Intervention: Control (discontinue all antihypertensive agents)
Number of subjects: 4071
Study 38174567 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-antiplatelet therapy (DAPT)
Number of subjects: 4841
Study 38174567 — intervention group
Group type: COMPARATOR
Intervention: Aspirin and placebo
Number of subjects: 4841
Study 38174568 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase (0.25 mg/kg)
Number of subjects: 1577
Study 38174568 — intervention group
Group type: COMPARATOR
Intervention: Alteplase (0.9 mg/kg)
Number of subjects: 1577
Study 38174577 — intervention group
Group type: EXPERIMENTAL
Intervention: erenumab
Number of subjects: 0
Study 38174577 — intervention group
Group type: COMPARATOR
Intervention: rimegepant
Number of subjects: 0
Study 38174569 — intervention group
Group type: EXPERIMENTAL
Intervention: Asundexian 50 mg daily
Number of subjects: 1808
Study 38174569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1808
Study 38174611 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA-assisted psychotherapy
Number of subjects: 0
Study 38174611 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic alliance
Number of subjects: 0
Study 38175228 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant transcranial direct current stimulation (tDCS) with intensive speech-language therapy for 3 weeks
Number of subjects: 110
Study 38175228 — intervention group
Group type: COMPARATOR
Intervention: Intensive speech-language therapy for 3 weeks
Number of subjects: 110
Study 38175251 — intervention group
Group type: EXPERIMENTAL
Intervention: 700 mg phosphorus
Number of subjects: 28
Study 38175251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 38175251 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphate with glucose
Number of subjects: 28
Study 38175251 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphate without glucose
Number of subjects: 28
Study 38175339 — intervention group
Group type: EXPERIMENTAL
Intervention: Total synovitis uptake (TSU)
Number of subjects: 19
Study 38175339 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic synovitis volume (MSV)
Number of subjects: 19
Study 38175364 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab treatment
Number of subjects: 764
Study 38175391 — intervention group
Group type: EXPERIMENTAL
Intervention: Itanet database project
Number of subjects: 1600
Study 38175448 — intervention group
Group type: EXPERIMENTAL
Intervention: neoadjuvant trastuzumab, pertuzumab, and docetaxel (DPH)
Number of subjects: 197
Study 38175448 — intervention group
Group type: COMPARATOR
Intervention: trastuzumab emtansine (T-DM1)
Number of subjects: 197
Study 38175448 — intervention group
Group type: EXPERIMENTAL
Intervention: baseline sTK1 levels
Number of subjects: 197
Study 38175448 — intervention group
Group type: EXPERIMENTAL
Intervention: sTK1 level after 2 and 4 cycles
Number of subjects: 197
Study 38175448 — intervention group
Group type: EXPERIMENTAL
Intervention: sTK1 activity at end of treatment visit
Number of subjects: 197
Study 38175448 — intervention group
Group type: EXPERIMENTAL
Intervention: sTK1 activity at baseline and cycle 2
Number of subjects: 197
Study 38175448 — intervention group
Group type: EXPERIMENTAL
Intervention: event-free survival (EFS)
Number of subjects: 197
Study 38175466 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenegermin 20 mcg/ml, 1 drop in the affected eye(s) 6 times/day for 8 weeks
Number of subjects: 37
Study 38175488 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam nasal spray administered in < 5 min after seizure start
Number of subjects: 3225
Study 38175488 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam nasal spray administered in ≥ 5 min after seizure start
Number of subjects: 3225
Study 38175595 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib
Number of subjects: 101
Study 38175595 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 101
Study 38175595 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 101
Study 38175627 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of fractionated stereotactic radiotherapy or whole-brain radiotherapy with pyrotinib (400 mg, once daily) and capecitabine (1000 mg/m2, twice daily, on days 1-14 of each 21-day cycle)
Number of subjects: 40
Study 38175642 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1RA
Number of subjects: 543595
Study 38175642 — intervention group
Group type: COMPARATOR
Intervention: Basal insulin
Number of subjects: 543595
Study 38175648 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application (ICUconnect) intervention
Number of subjects: 111
Study 38175648 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 111
Study 38175648 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application (ICUconnect) intervention for White family members
Number of subjects: 111
Study 38175648 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application (ICUconnect) intervention for Black family members
Number of subjects: 111
Study 38175669 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy + Endocrine Therapy (ET)
Number of subjects: 49
Study 38175669 — intervention group
Group type: EXPERIMENTAL
Intervention: CDK4/6-inhibitors + Endocrine Therapy (ET)
Number of subjects: 49
Study 38175837 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-wide mass drug administration (cMDA)
Number of subjects: 18
Study 38175837 — intervention group
Group type: COMPARATOR
Intervention: School-based mass drug administration (MDA)
Number of subjects: 18
Study 38175920 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 38176013 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiation of breastfeeding or provision of expressed breast milk
Number of subjects: 579
Study 38176013 — intervention group
Group type: COMPARATOR
Intervention: HCV viremia (detectable viral load during pregnancy)
Number of subjects: 579
Study 38176013 — intervention group
Group type: COMPARATOR
Intervention: Undetectable viral load during pregnancy
Number of subjects: 579
Study 38176013 — intervention group
Group type: EXPERIMENTAL
Intervention: Private insurance
Number of subjects: 579
Study 38176013 — intervention group
Group type: COMPARATOR
Intervention: Public insurance or no insurance
Number of subjects: 579
Study 38176013 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of breastfeeding
Number of subjects: 579
Study 38176019 — intervention group
Group type: EXPERIMENTAL
Intervention: Various biomarkers tested for early-stage ovarian cancer detection
Number of subjects: 131
Study 38176019 — intervention group
Group type: COMPARATOR
Intervention: CA 125
Number of subjects: 131
Study 38176019 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers with better sensitivity
Number of subjects: 131
Study 38176122 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-determined sequence exercise program (SDSG, n = 34)
Number of subjects: 94
Study 38176122 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training group (STG, n = 30)
Number of subjects: 94
Study 38176122 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG, n = 30)
Number of subjects: 94
Study 38176228 — intervention group
Group type: EXPERIMENTAL
Intervention: Best medical therapy (BMT) involving antiplatelet agents, blood pressure control, and statins
Number of subjects: 307
Study 38176228 — intervention group
Group type: COMPARATOR
Intervention: Stable plaque
Number of subjects: 307
Study 38176228 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaque progression
Number of subjects: 307
Study 38176228 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral carotid stenosis >60%
Number of subjects: 307
Study 38176391 — intervention group
Group type: EXPERIMENTAL
Intervention: Schema Therapy (ST)
Number of subjects: 292
Study 38176391 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 292
Study 38176391 — intervention group
Group type: COMPARATOR
Intervention: Individual Supportive Therapy (IST)
Number of subjects: 292
Study 38176682 — intervention group
Group type: EXPERIMENTAL
Intervention: HemoCue 201+ analyzer using venous blood
Number of subjects: 0
Study 38176682 — intervention group
Group type: EXPERIMENTAL
Intervention: HemoCue 201+ analyzer using pooled capillary blood
Number of subjects: 0
Study 38176682 — intervention group
Group type: EXPERIMENTAL
Intervention: HemoCue 201+ analyzer using single-drop capillary blood
Number of subjects: 0
Study 38176682 — intervention group
Group type: COMPARATOR
Intervention: Reference method using Sysmex XN-450 hematology analyzer with venous blood
Number of subjects: 0
Study 38176698 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning model using facial expressions
Number of subjects: 155
Study 38176698 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning model combining facial expressions and vital signs
Number of subjects: 155
Study 38176698 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning models using combined physiological signals (vital signs, ANI)
Number of subjects: 155
Study 38176698 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute ANI
Number of subjects: 155
Study 38176698 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative ANI
Number of subjects: 155
Study 38176782 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavacamten 5 mg once daily
Number of subjects: 231
Study 38176840 — intervention group
Group type: EXPERIMENTAL
Intervention: MCPAP for Moms
Number of subjects: 312
Study 38176840 — intervention group
Group type: EXPERIMENTAL
Intervention: PRISM
Number of subjects: 312
Study 38176857 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine for 6 weeks
Number of subjects: 0
Study 38176857 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) for 6 weeks
Number of subjects: 0
Study 38176857 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Amantadine and TMS for 6 weeks
Number of subjects: 0
Study 38176857 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham control) for 6 weeks
Number of subjects: 0
Study 38176857 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine and/or TMS
Number of subjects: 0
Study 38176863 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-assisted CT-based lung cancer prediction tool (LCP)
Number of subjects: 2000
Study 38176863 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 2000
Study 38176866 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen-ozone therapy 2-3 times a week for 6 weeks (maximum of 15 sessions) with oral antibiotic therapy
Number of subjects: 186
Study 38176866 — intervention group
Group type: COMPARATOR
Intervention: Oral antibiotic therapy prescribed at baseline
Number of subjects: 186
Study 38176872 — intervention group
Group type: EXPERIMENTAL
Intervention: On Your Own Feet Ahead theoretical framework
Number of subjects: 0
Study 38176874 — intervention group
Group type: COMPARATOR
Intervention: Control+ONS
Number of subjects: 200
Study 38176874 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB+ONS
Number of subjects: 200
Study 38176874 — intervention group
Group type: EXPERIMENTAL
Intervention: VT+ONS
Number of subjects: 200
Study 38176874 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB+VT+ONS
Number of subjects: 200
Study 38176875 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Therapy (ET) - 12-week rehabilitation programme
Number of subjects: 116
Study 38176875 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shockwave Therapy (ESWT) - four sessions with 1 week rest between sessions during 1 month
Number of subjects: 116
Study 38176875 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Percutaneous Irrigation of Calcific Tendinopathy (US-PICT) - two sessions with 3 months of rest between sessions
Number of subjects: 116
Study 38176875 — intervention group
Group type: COMPARATOR
Intervention: Wait-and-see group - no intervention during the 12-month follow-up
Number of subjects: 116
Study 38176875 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial questionnaires
Number of subjects: 116
Study 38176879 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention
Number of subjects: 6480
Study 38176879 — intervention group
Group type: COMPARATOR
Intervention: Usual care (not offering telemedicine)
Number of subjects: 6480
Study 38176899 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-based CRC test (Shield, Guardant Health)
Number of subjects: 2004
Study 38176899 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2004
Study 38177042 — intervention group
Group type: EXPERIMENTAL
Intervention: Second autologous hematopoietic stem cell transplantation (aHSCT)
Number of subjects: 4
Study 38177091 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive Alarm (PA) for hypoglycaemia
Number of subjects: 20
Study 38177116 — intervention group
Group type: EXPERIMENTAL
Intervention: RIV4
Number of subjects: 1407
Study 38177116 — intervention group
Group type: EXPERIMENTAL
Intervention: RIV4 or ccIIV4
Number of subjects: 1407
Study 38177116 — intervention group
Group type: COMPARATOR
Intervention: IIV4, ccIIV4, RIV4
Number of subjects: 1407
Study 38177128 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-exertional malaise induction in patients with long COVID
Number of subjects: 0
Study 38177128 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 38177178 — intervention group
Group type: EXPERIMENTAL
Intervention: High platelet reactivity (PRU ≥ 252)
Number of subjects: 11714
Study 38177178 — intervention group
Group type: EXPERIMENTAL
Intervention: High aspirin reaction unit (≥ 414)
Number of subjects: 11714
Study 38177178 — intervention group
Group type: EXPERIMENTAL
Intervention: Early stent thrombosis (EST) group
Number of subjects: 11714
Study 38177178 — intervention group
Group type: COMPARATOR
Intervention: Non-EST group
Number of subjects: 11714
Study 38177509 — intervention group
Group type: EXPERIMENTAL
Intervention: Core stability exercises
Number of subjects: 52
Study 38177509 — intervention group
Group type: COMPARATOR
Intervention: Rebound therapy
Number of subjects: 52
Study 38177554 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve Gastrectomy (SG)
Number of subjects: 46
Study 38177554 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical controls (NS)
Number of subjects: 46
Study 38177805 — intervention group
Group type: EXPERIMENTAL
Intervention: semaglutide
Number of subjects: 0
Study 38177805 — intervention group
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Number of subjects: 0
Study 38177805 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 38177851 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-mefloquine
Number of subjects: 726
Study 38177851 — intervention group
Group type: COMPARATOR
Intervention: Praziquantel (standard care)
Number of subjects: 726
Study 38177853 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotorasib plus panitumumab
Number of subjects: 0
Study 38177852 — intervention group
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin plus pomalidomide and dexamethasone
Number of subjects: 87
Study 38177855 — intervention group
Group type: EXPERIMENTAL
Intervention: bidridistrogene xeboparvovec, an adeno-associated virus-based gene therapy
Number of subjects: 0
Study 38177986 — intervention group
Group type: COMPARATOR
Intervention: Gut microbiota composition analysis using Shannon index, Simpson index, principal coordinates analysis, and Wilcoxon rank-sum test.
Number of subjects: 33
Study 38177986 — intervention group
Group type: COMPARATOR
Intervention: Plasma concentrations of tryptophan metabolites compared using t tests and analysis of variance.
Number of subjects: 33
Study 38177986 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratio of kynurenic acid to quinolinic acid evaluated using receiver operating characteristic curve.
Number of subjects: 33
Study 38178036 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear Implantation
Number of subjects: 100
Study 38178048 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment modalities for SE
Number of subjects: 3000
Study 38178048 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG data collection
Number of subjects: 3000
Study 38178048 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with outcome and refractoriness
Number of subjects: 3000
Study 38178051 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthopaedic Manipulation Techniques of LSLR (OMT-LSLR)
Number of subjects: 50
Study 38178051 — intervention group
Group type: COMPARATOR
Intervention: Sham manipulation treatment
Number of subjects: 50
Study 38178156 — intervention group
Group type: EXPERIMENTAL
Intervention: Fistula repair surgery
Number of subjects: 1000
Study 38178156 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative inquiry with key stakeholders
Number of subjects: 1000
Study 38178168 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 100
Study 38178168 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol and sufentanil in combination (P + S)
Number of subjects: 100